| Schedule of Option Activity Under Our Stock Option Plans |
A summary of option activity under our stock option
plans (excluding the NoveCite and Citius Oncology Stock Plans) is presented below:
| | | Option
Shares | | | Weighted-
Average
Exercise
Price | | | Weighted-
Average
Remaining
Contractual
Term | | Aggregate
Intrinsic
Value | | | Outstanding at September 30, 2025 | | | 839,510 | | | $ | 30.09 | | | 6.90 years | | $ | 0.00 | | | Granted | | | - | | | | - | | | | | | | | | Exercised | | | - | | | | - | | | | | | | | | Forfeited or expired | | | (3,200 | ) | | | 234.98 | | | | | | | | | Outstanding at June 30, 2026 | | | 836,310 | | | $ | 29.31 | | | 6.09 years | | $ | 0.00 | | | Exercisable at June 30, 2026 | | | 685,643 | | | $ | 33.07 | | | 5.66 years | | $ | 0.00 | | A summary of option activity under the Citius Oncology stock plans
is presented below:
| | | Shares | | | Weighted-
Average
Exercise
Price | | | Weighted-
Average
Remaining
Contractual
Term | | Aggregate
Intrinsic
Value | | | Outstanding at September 30, 2025 | | | 18,100,000 | | | $ | 1.83 | | | 8.21 years | | $ | 5,386,000 | | | Granted | | | - | | | | - | | | | | | | | | Forfeited | | | - | | | | - | | | | | | | | | Outstanding at June 30, 2026 | | | 18,100,000 | | | $ | 1.83 | | | 7.27 years | | $ | - | | | Exercisable at June 30, 2026 | | | 11,316,667 | | | $ | 1.90 | | | 7.02 years | | $ | - | |
|
| Schedule of Exercise of Outstanding Warrants |
The following table summarizes the warrants outstanding at June 30, 2026: | | | Exercise
Price | | | Shares | | | Expiration
Dates | | August 2018 Offering Investors | | $ | 28.75 | | | | 156,863 | | | August 14, 2026 | | August 2018 Offering Agent | | $ | 39.84 | | | | 7,576 | | | August 8, 2026 | | September 2019 Offering Investors | | $ | 19.25 | | | | 111,732 | | | September 27, 2026 | | September 2019 Offering Underwriter | | $ | 27.97 | | | | 7,774 | | | September 27, 2026 | | January 2021 Offering Investors | | $ | 30.78 | | | | 123,648 | | | July 27, 2026 | | January 2021 Offering Agent | | $ | 40.44 | | | | 14,065 | | | July 27, 2026 | | May 2023 Offering Investors | | $ | 37.50 | | | | 500,000 | | | May 8, 2028 | | May 2023 Offering Agent | | $ | 37.50 | | | | 35,000 | | | May 3, 2028 | | April 2024 Offering Investors | | $ | 18.75 | | | | 857,143 | | | October 30, 2029 | | April 2024 Offering Agent | | $ | 21.875 | | | | 60,000 | | | April 25, 2029 | | November 2024 Offering Investors | | $ | 6.25 | | | | 480,000 | | | November 18, 2029 | | November 2024 Offering Agent | | $ | 7.8125 | | | | 33,600 | | | November 15, 2029 | | January 2025 Offering Investors | | $ | 3.91 | | | | 743,496 | | | January 8, 2030 | | January 2025 Offering Agent | | $ | 5.0438 | | | | 52,045 | | | January 7, 2030 | | April 2025 Offering Agent | | $ | 1.4375 | | | | 121,739 | | | April 1, 2030 | | June 2025 Offering Investor | | $ | 1.00 | | | | 9,840,000 | | | June 11, 2027 | | June 2025 Offering Agent | | $ | 1.525 | | | | 344,400 | | | June 11, 2027 | | October 2025 Offering Investor | | $ | 1.40 | | | | 3,973,510 | | | October 21, 2030 | | October 2025 Placement Agent | | $ | 1.8875 | | | | 278,146 | | | October 20, 2030 | | December 2025 Note Payable Extension | | $ | 1.26 | | | | 75,000 | | | January 2, 2031 | | April 2026 Offering Investors | | $ | 0.86 | | | | 5,076,143 | | | April 24, 2031 | | April 2026 Offering Agent | | $ | 1.2313 | | | | 355,330 | | | April 23, 2031 | | | | | | | | | 23,247,210 | | | | The following table summarizes the warrants outstanding at June 30, 2026: | | | Exercise
Price | | | Number | | | Expiration Dates | | July 2025 Offering Agent | | $ | 1.65 | | | | 272,727 | | | July 17, 2030 | | July 2025 Prior Offering Agent | | $ | 1.65 | | | | 477,273 | | | July 17, 2030 | | September 2025 Offering Agent | | $ | 1.92 | | | | 205,714 | | | March 10, 2031 | | September 2025 Prior Offering Agent | | $ | 2.1875 | | | | 360,000 | | | March 10, 2031 | | December 2025 Offering Investors | | $ | 0.0001 | | | | 7,046,000 | | | None | | December 2025 Offering Investors | | $ | 0.90 | | | | 15,697,024 | | | May 22, 2031 | | December 2025 Placement Offering Agent | | $ | 1.3625 | | | | 1,155,963 | | | December 8, 2030 | | December 2025 Prior Offering Agent | | $ | 1.199 | | | | 660,550 | | | December 8, 2030 | | May 2026 Investor | | $ | 0.90 | | | | 25,555,556 | | | May 22, 2031 | | May 2026 Offering Agent | | $ | 1.125 | | | | 894,444 | | | June 18, 2031 | | May 2026 Prior Offering Agent | | $ | 1.199 | | | | 511,111 | | | June 18, 2031 | | May 2026 Lenders | | $ | 0.90 | | | | 1,111,111 | | | May 22, 2031 | | | | | | | | | 53,947,473 | | | |
|
| Schedule of Common Stock Reserved for Future Issuances |
A summary of common stock reserved for future
issuances by Citius Pharma excluding all subsidiaries as of June 30, 2026 is as follows:
| Stock plan options outstanding | |
| 836,310 | |
| Stock plan shares available for future grants | |
| 118,000 | |
| Warrants outstanding | |
| 23,247,210 | |
| Total | |
| 24,201,520 | |
A summary of common stock reserved for future
issuances by Citius Oncology as of June 30, 2026 is as follows:
| Stock plan options outstanding | |
| 18,100,000 | |
| Restricted stock units | |
| 11,950,000 | |
| Stock plan shares available for future grants | |
| 14,950,000 | |
| Warrants outstanding | |
| 53,947,473 | |
| Total | |
| 98,947,473 | |
|